CM Life Sciences III (CMLTU) to Combine with EQRx in $3.5Bn Deal

CMLS III (NASDAQ:CMLTU) has entered into a definitive agreement to combine with biotech firm EQRx at an enterprise value of $3.54 billion. Cambridge, Massachusetts-based EQRx is developing a range of drug candidates both generated in-house and licensed from peers with an aim to reducing the overall cost of pharmaceutical rollouts. The combined company is expected
Read More